Prokarium Ltd.

Prokarium Ltd. , based in the UK, is a biotechnology company dedicated to advancing innovative microbial immunotherapy solutions for cancer treatment, particularly bladder cancer. Founded in 2012 and headquartered in London, UK, Prokarium Ltd. specializes in biopharmaceuticals, focusing on microbial immunotherapies.

The company has raised a total of USD 30. 00 mn through various funding rounds, with the latest round occurring on January 10, 2023, supported by investors such as Ginkgo Bioworks and Flerie Invest. Kristen Albright serves as the CEO, steering the company towards impactful cancer treatment solutions. Prokarium is a biopharmaceutical company specializing in innovative cancer treatments, focusing primarily on microbial immunotherapy.

Its core product offerings include a proprietary strain of Salmonella, ZH9, utilized as a microbial immunotherapy platform to treat bladder cancer. The lead program is designed to transform the treatment paradigm for non-muscle invasive bladder cancer cases. Prokarium leverages synthetic biology to create an oral immune training agent aimed at restoring anti-tumor responses and enhancing the effectiveness of current immunotherapies. The firm primarily targets markets in North America and Europe, addressing the critical unmet needs of cancer patients with existing therapeutic options.

In the most recent year, Prokarium reported no revenue, with an EBITDA of -USD 14,245,415. 80 for 2023. The company’s revenue model is based on partnerships and collaborations with healthcare providers and research institutions to advance its clinical programs, focusing on successful clinical milestones and potential commercialization of its therapies. Prokarium may also explore subscription services related to its Living Cures platform, which offers programmable therapeutics tailored for specific patient populations.

Prokarium's growth strategy includes advancing its clinical programs and expanding its product offerings through research and development. The recent funding of USD 30. 00 mn, raised in January 2023, will support these initiatives, particularly in clinical trial advancements. The company is targeting further penetration into North American and European markets, with plans to enhance its portfolio of innovative cancer treatments aimed at improving patient outcomes.